Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 11:17 PM ET

Pharmaceuticals

Company Overview of Celsus Therapeutics Plc

Company Overview

As of September 18, 2015, Celsus Therapeutics Plc was acquired by Akari Therapeutics, Plc, in a reverse merger transaction. Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company’s principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases. The company w...

The Gridiron Building

One Pancras Square

London,  N1C 4AG

United Kingdom

Founded in 2004

5 Employees

Phone:

44 20 3318 3004

Fax:

44 20 3318 3004

Key Executives for Celsus Therapeutics Plc

Celsus Therapeutics Plc does not have any Key Executives recorded.

Celsus Therapeutics Plc Key Developments

Celsus Therapeutics Plc, Special/Extraordinary Shareholders Meeting, Sep 16, 2015

Celsus Therapeutics Plc, Special/Extraordinary Shareholders Meeting, Sep 16, 2015. Agenda: To approve private placement to raise about $70 million with a group of investors at about $1.58 per American Depositary Share, or $0.158 per ordinary share; and to approve acquisition of Volution Immuno Pharmaceuticals.

Celsus Therapeutics Plc Announces Board Changes

Effective as of immediately following Celsus Therapeutics Plc's annual general meeting of shareholders, Amos Eiran, formerly a Class B director of the board of directors of the company and Robert Francis Doman, formerly a Class A director of the board, were no longer serving as members of the board as they were not nominated for re-election by the board and their terms expired. Following the annual meeting, the compensation committee of the board is comprised of Mark Cohen, David Sidransky, M.D. and Johnson Lau, M.D., the nominating and governance committee of the board is comprised of Mark Cohen, Dr. Sidransky and Dr. Lau, and the audit committee of the board is comprised of Allan Shaw, Dr. Lau and Dr. Sidransky. As of the date of the annual meeting, Mr. Cohen no longer has the title executive chairman but remains as chairman of the board of directors. Because Mr. Cohen is not, and never has been an employee of the company, and based on his background, employment and affiliations, the board has determined that he qualifies as an independent director under NASDAQ Marketplace Rules.

Celsus Therapeutics Plc, Annual General Meeting, Jul 15, 2015

Celsus Therapeutics Plc, Annual General Meeting, Jul 15, 2015., at 13:00 US Eastern Standard Time. Location: 24 West 40 Street, 8 Floor. Agenda: To receive the accounts of the company for the year ended December 31, 2014 together with the report of the auditors of the company; to re-elect directors; and to re-appoint Kost, Forer Gabbay & Kasierer, a member of Ernst & Young Global, as auditors of Celsus to hold office until the conclusion of the next general meeting.

Similar Private Companies By Industry

Company Name Region
Croda Health Care Europe
Kent Pharmaceuticals Limited Europe
Alimera Sciences Limited Europe
Relonchem Limited Europe
Muscagen Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 13, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celsus Therapeutics Plc, please visit www.celsustx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.